Literature DB >> 33719833

Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.

Megan Othus1,2, Guillermo Garcia-Manero3, John Godwin4, James Weick5, Derek Stirewalt2, Frederick Appelbaum2, Harry Erba6, Elihu Estey2.   

Abstract

Among acute myeloid leukemia (AML) patients treated with 7 + 3 induction, we evaluate the association between complete morphologic remission (CR) and long-term overall survival (OS) over four decades. We analyzed 1247 patients age ≤65 randomized to 7 + 3 arms from five SWOG studies. OS has improved over the four decades. Hazards for death in the two most recent studies fell after year 2. In multivariable models, decade of therapy was the most important variable with respect to long-term survival and CR by day 100 the second most important variable. Protocol/decade, which captures many factors not included in our multivariable model, was the most important predictor of being alive at year 2 or 3. The next most important factor was achievement of first CR by day 100.

Entities:  

Keywords:  Acute myeloid leukemia; complete remission; induction; overall survival

Mesh:

Substances:

Year:  2021        PMID: 33719833      PMCID: PMC8647999          DOI: 10.1080/10428194.2021.1885663

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  17 in total

1.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

2.  A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

Authors:  J K Weick; K J Kopecky; F R Appelbaum; D R Head; L L Kingsbury; S P Balcerzak; J N Bickers; H E Hynes; J L Welborn; S R Simon; M Grever
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

3.  Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.

Authors:  Alan K Burnett; Nigel H Russell; Ann E Hunter; Donald Milligan; Steven Knapper; Keith Wheatley; John Yin; Mary F McMullin; Sahra Ali; David Bowen; Robert K Hills
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

4.  Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.

Authors:  M de Lima; S S Strom; M Keating; H Kantarjian; S Pierce; S O'Brien; E Freireich; E Estey
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

5.  Reduced mortality after allogeneic hematopoietic-cell transplantation.

Authors:  Ted A Gooley; Jason W Chien; Steven A Pergam; Sangeeta Hingorani; Mohamed L Sorror; Michael Boeckh; Paul J Martin; Brenda M Sandmaier; Kieren A Marr; Frederick R Appelbaum; Rainer Storb; George B McDonald
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

6.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

7.  The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.

Authors:  A K Burnett; R K Hills; A E Hunter; D Milligan; W J Kell; K Wheatley; J Yin; M F McMullin; H Dignum; D Bowen; N H Russell
Journal:  Leukemia       Date:  2012-08-14       Impact factor: 11.528

8.  Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.

Authors:  G Juliusson; J Abrahamsson; V Lazarevic; P Antunovic; Å Derolf; H Garelius; S Lehmann; K Myhr-Eriksson; L Möllgård; B Uggla; A Wahlin; L Wennström; M Höglund
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528

9.  Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.

Authors:  Ali Bazarbachi; Christoph Schmid; Myriam Labopin; Dietrich Beelen; Igor Wolfgang Blau; Victoria Potter; Riitta Niittyvuopio; Gerard Socié; Didier Blaise; Jaime Sanz; Fabio Ciceri; Iman Abou Dalle; Alexandros Spyridonidis; Gesine Bug; Jordi Esteve; Bipin N Savani; Arnon Nagler; Mohamad Mohty
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 12.531

10.  Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life.

Authors:  H Bower; T M-L Andersson; M Björkholm; P W Dickman; P C Lambert; Å R Derolf
Journal:  Blood Cancer J       Date:  2016-02-05       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.